Jun 15, 2025, 15:28
CAR-T Cell Therapy Extended Survival by 40% in Patients With Advanced Gastric Cancer – Cancer Research Institute
Cancer Research Institute (CRI) shared a post on LinkedIn:
“In a new clinical trial, researchers at ASCO25 described, CAR T cell therapy extended survival by 40% in patients with advanced gastric cancer.
Those who received CAR T cell therapy, results published in The Lancet Group showcase, lived an average of 7.9 months, compared with 5.5 months for those on standard care.
‘This represents a groundbreaking milestone for the field of CAR T therapies against solid tumors,’ says CRI Scientific Advisory Council member Dr. Carl June of Penn Medicine, University of Pennsylvania Health System. “
More posts featuring Cancer Research Institute
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 15, 2025, 14:59
Jun 15, 2025, 14:09